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Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CAD ¼ coronary artery disease
CCS ¼ Canadian Cardiovascular Society
CTO ¼ chronic total occlusion
FFR ¼ fractional flow reserve
HF ¼ heart failure
IVUS ¼ intravascular ultrasound
LAD ¼ left anterior descending artery
LIMA ¼ left internal mammary artery
LV ¼ left ventricular
LVEF ¼ left ventricular ejection fraction
MI ¼ myocardial infarction
PCI ¼ percutaneous coronary intervention
STEMI ¼ ST-segment elevation myocardial
infarction
TIMI ¼ Thrombolysis In Myocardial
Infarction
UA/
NSTEMI
¼ unstable angina/non–ST-segment
elevation myocardial infarction
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ABSTRACT
The American College of Cardiology Foundation (ACCF),
Society for Cardiovascular Angiography and Interventions,
Society of Thoracic Surgeons, and the American Associa-
tion for Thoracic Surgery, along with key specialty and sub-
specialty societies, conducted an update of the appropriate
use criteria (AUC) for coronary revascularization fre-
quently considered. In the initial document, 180 clinical
scenarios were developed to mimic patient presentations
encountered in everyday practice and included information
on symptom status, extent of medical therapy, risk level as
assessed by noninvasive testing, and coronary anatomy.
This update provides a reassessment of clinical scenarios
the writing group felt to be affected by significant changes
in the medical literature or gaps from prior criteria. The
methodology used in this update is similar to the initial doc-
ument, and the definition of appropriateness was un-
changed. The technical panel scored the clinical scenarios
on a scale of 1 to 9. Scores of 7 to 9 indicate that revascu-
larization is considered appropriate and likely to improve
patients’ health outcomes or survival. Scores of 1 to 3 indi-
cate revascularization is considered inappropriate and un-
likely to improve health outcomes or survival. Scores in
the mid-range (4 to 6) indicate a clinical scenario for which
the likelihood that coronary revascularization will improve
health outcomes or survival is uncertain.
In general, as seen with the prior AUC, the use of coro-
nary revascularization for patients with acute coronary syn-
dromes and combinations of significant symptoms and/or
ischemia is appropriate. In contrast, revascularization of
asymptomatic patients or patients with low-risk findings
on noninvasive testing and minimal medical therapy are
viewed less favorably. The technical panel felt that based
on recent studies, coronary artery bypass grafting remains
an appropriate method of revascularization for patients
with high burden of coronary artery disease (CAD). Addi-
tionally, percutaneous coronary intervention may have
a role in revascularization of patients with high burden of
CAD. The primary objective of the appropriate use criteriardiovascular Surgery c Volume 143, Number 4 781
Clinical Guidelines Patel et alis to improve physician decision making and patient educa-
tion regarding expected benefits from revascularization and
to guide future research.
PREFACE
The American College of Cardiology Foundation
(ACCF), in collaboration with the Society for Cardiovascu-
lar Angiography and Interventions (SCAI), the Society of
Thoracic Surgeons (STS), the American Association for
Thoracic Surgery (AATS), and other societies, developed
and published in 2009 appropriate use criteria (AUC) for cer-
tain clinical scenarios in which coronary revascularization
could be used in an effort to address the rational use of
coronary revascularization in the delivery of high-quality
care. This document is the first focused update of the original
document and includes new literature published since the
original document and gaps noted during implementation.
The publication of AUC reflects one of several ongoing ef-
forts by the ACCF and its partners to assist clinicians caring
for patients with cardiovascular diseases and in support of
high-quality cardiovascular care. TheACCF/AmericanHeart
Association (AHA) clinical practice guidelines provide
a foundation for summarizing evidence-based cardiovascular
care and, when evidence is lacking, provide expert consensus
opinion that is approved in review by the ACCF and AHA.
However, in many areas, variability remains in the use of car-
diovascular procedures, raising questions of over- or under-
use. The AUC provide a practical standard upon which to
assess and better understand variability.
We are grateful to the technical panel and its chair, Fred-
erick A. Masoudi, MD, MSPH, FACC, FAHA, a profes-
sional group with a wide range of skills and insights, for
their thoughtful and thorough deliberation of the merits of
coronary revascularization for various clinical scenarios.
We would also like to thank the parent AUC Task Force
and the ACCF staff, Joseph M. Allen and Lea Binder, for
their exceptionally skilled support in the generation of
this document.
Manesh R. Patel, MD, FACC
Chair, Coronary Revascularization Writing Group
Michael J. Wolk, MD, MACC
Chair, Appropriate Use Criteria Task Force
INTRODUCTION
This report is a focused update of the AUC for coronary
revascularization published in 2009.1 The increasing preva-
lence of coronary artery disease (CAD), continued advances
in surgical and percutaneous techniques for revasculariza-
tion and concomitant medical therapy for CAD, and the
costs of revascularization have resulted in heightened inter-
est regarding the appropriate use of coronary revasculariza-
tion. Clinicians, payers, and patients are interested in the
specific benefits of revascularization. Inappropriate revas-
cularization may be harmful to patients and generate782 The Journal of Thoracic and Cardiovascular Surgunwarranted costs to the healthcare system, whereas appro-
priate revascularization procedures can improve patients’
clinical outcomes.
As in the original AUC document, the same classification
scheme with ratings of appropriate, uncertain, and inappro-
priate was used. The uncertain category can cause confu-
sion in the interpretation of the AUC and can imply
several meanings within its definition. First, the rating of
uncertain is used when pertinent literature is either not
available or when true discrepancies exist. Second, it is im-
possible to include every relevant piece of clinical informa-
tion (eg, age, sex, diabetes) in the individual clinical
scenarios. Attempting to do that may result in an unmanage-
able number of clinical scenarios and thus compromise the
usefulness of the AUC in daily practice. The practice of
medicine is full of uncertainties that require a thoughtful
clinician to use his or her best judgment about each patient
to reach decisions about management. Therefore, a rating of
uncertain may be assigned by members of the technical
panel if clinical information not provided might affect their
individual rating, causing a shift into either the appropriate
or inappropriate category.
A rating of uncertain means simply what the name im-
plies, and depending on additional factors, it can be appro-
priate or inappropriate to perform revascularization. The
writing group emphasizes that uncertain indications are
not inappropriate. Rather, they reflect clinical scenarios
that are reasonable for performing revascularization, but ad-
ditional clinical factors should be considered or further re-
search is needed to more definitively define the benefits of
treatment for patients.
All prior AUC publications have reflected an ongoing ef-
fort to critically and systematically create, review, and cat-
egorize the appropriateness of certain cardiovascular
diagnostic tests, whereas the AUC for coronary revascular-
ization remains the only document addressing treatment.
The writing group and technical panel members for this up-
date are identical to the initial AUC (with only 1 exception)
and comprised of members from relevant professional soci-
eties including both practicing interventional cardiologists
and a cardiothoracic surgeon.
For the majority of clinical scenarios, the technical panel
only considered the appropriate use of revascularization ir-
respective of whether this was accomplished by percutane-
ous coronary intervention (PCI) or coronary artery bypass
graft surgery (CABG). However, in a select subgroup of
clinical scenarios in which revascularization is generally
considered appropriate, the appropriateness of PCI and
CABG, individually, was considered. In this subgroup, it
was recognized that a focused update could be necessary
following publication of the SYNTAX (Synergy Between
PCI With TAXUS and Cardiac Surgery) trial.2 Therefore,
in this update, thewriting group identified 4 indications pos-
sibly affected by results of the SYNTAX trial forery c April 2012
Patel et al Clinical Guidelinesreexamination. The writing group also split 2 of the indica-
tions to represent levels of disease burden, recognizing,
however, that the ability to reproducibly quantify the SYN-
TAX score in routine clinical practice has challenges. Also
in this subgroup, the variables of diabetes and depressed left
ventricular function were included in the initial AUC, but
these were combined for the update because all indications
with these variables were rated the same in the previous
scores by the technical panel.
In addition, since the publication of the original docu-
ment, efforts to implement data collection protocols related
to the AUC indications identified a gap in the clinical
scenarios related to lower-risk unstable angina/non–ST-
segment elevation myocardial infarction (UA/NSTEMI)
patients and asymptomatic patients with 1- or 2-vessel
CAD not involving the proximal left anterior descending
artery (LAD) in whom no noninvasive testing had been per-
formed. Although limited new evidence is available for
these patient populations since publication, the writing
group developed indications to address these previous
omissions.
METHODS
A detailed description of the methods used for rating the
selected clinical indications is found in a previous publica-
tion, ‘‘ACCF Proposed Method for Evaluating the Appro-
priateness of Cardiovascular Imaging.’’3 Briefly, this
process combines evidence-based medicine and practice
experience by engaging a technical panel in a modified Del-
phi exercise. The technical panel is created from nomina-
tions given by multiple relevant professional societies and
provider-led organizations as well as from health policy
and payer communities. To preserve objectivity, technical
panels are created so as to not include a majority of individ-
uals whose livelihood is tied to the technology under
evaluation.
In making its appropriate use determinations, the techni-
cal panel is provided with summaries of the relevant evi-
dence from the medical literature and practice guidelines.
Panelists are first asked individually, and then collectively,
to assess the benefits and risks of a test or procedure in
the context of the potential benefits to patients’ outcomes
and an implicit understanding of the associated resource
use and costs. After the rating process, the final appropriate
use ratings are summarized using an established rigorous
methodology.4
Indication Development
Appropriate use criteria are based on current understand-
ing of the technical capabilities and potential patient bene-
fits of the procedures examined. The AUC are also
developed to identify common clinical scenarios—but
they cannot possibly include every conceivable patient pre-
sentation. The term indication is used interchangeably withThe Journal of Thoracic and Caclinical scenario in the document for brevity and does not
imply that a procedure should necessarily be performed.
Some patients seen in clinical practice are not represented
in these appropriate use criteria or have additional extenuat-
ing features that would alter the appropriateness of treat-
ment as compared with the clinical scenarios presented.
Additionally, although AUC indications and ratings are
shaped by the guidelines, the AUC often contain more de-
tailed clinical scenarios than the more generalized situa-
tions covered in clinical practice guidelines, and thus,
subtle differences between these 2 guidance tools may be
possible. Tominimize this possibility, the coronary revascu-
larization criteria were updated in conjunction with mem-
bers of the ACCF/AHA PCI and CABG revascularization
guideline committees.
Appropriate use criteria are intended to assist patients and
clinicians, but are not intended to diminish the acknowledged
difficulty or uncertainty of clinical decision making and can-
not act as substitutes for sound clinical judgment and practice
experience. Rather, the aim of these criteria is to allow assess-
ment of utilization patterns for a test or procedure.Comparing
utilization patterns across a large subset of provider’s patients
can allow for an assessment of a provider’smanagement strat-
egies with those of his/her peers. The ACCF and its collabo-
rators believe that an ongoing review of one’s practice using
these criteria will help guide a more effective, efficient, and
equitable allocation of healthcare resources, and ultimately,
better patient outcomes.
The indications went through external review by multiso-
ciety and specialty representation for the 2009 document.
Because of the narrow focus, the indications were not sent
for external review for this update.
Scope of Indications
As previously described, the indications for coronary re-
vascularization were developed considering the following
common variables:
a. The clinical presentation (eg, acute coronary syndrome,
stable angina);
b. Severity of angina (asymptomatic, Canadian Cardiovas-
cular Society [CCS] Class I, II, III, or IV);
c. Extent of ischemia on noninvasive testing and the pres-
ence or absence of other prognostic factors, such as con-
gestive heart failure, depressed left ventricular function,
or diabetes;
d. Extent of medical therapy; and
e. Extent of anatomic disease (1-, 2-, 3-vessel disease, with
or without proximal LAD or left main coronary disease).
The clinical scenarios developed include coronary anat-
omy, as this is the focus of much of the previous literature
on coronary revascularization. However, the writing group
recognizes that for everyday patient care, symptom status,
ischemic burden, and level of medical therapy often playrdiovascular Surgery c Volume 143, Number 4 783
Clinical Guidelines Patel et ala critical role in decision making even before the coronary
anatomy has been defined by angiography. It is important to
note that the indications focus on revascularization, percu-
taneous or surgical, and do not address diagnostic catheter-
ization or coronary angiography; these criteria are currently
under development.
Technical Panel Selection
Stakeholders were given the opportunity to participate in
the AUC process by submitting nominees from their organi-
zations through a call for nominations announced in the
summer of 2006. From this list of nominees, the AUC
Task Force and writing group selected technical panel
members to ensure an appropriate balance with respect to
expertise. The 17-member technical panel was composed
of 4 interventional cardiologists, 4 cardiovascular surgeons,
8 members representing noninterventional cardiologists,
other physicians who treat patients with cardiovascular dis-
ease, health outcome researchers, and 1 medical officer
from a health plan. For the update of the AUC for coronary
revascularization, the same technical panelists (with 1 ex-
ception) from the original document published in 2009
were reconvened to rerate the 15 clinical scenarios included
in the focused update.
Rating Process and Scoring
The technical panel members first rated indications inde-
pendently. Then, the technical panel participated in 2 con-
ferences calls for a discussion of each indication. After
the discussion, panelists independently provided their final
scores for each indication. Each panelist had equal weight
in producing the final result for the indications and was
not forced into consensus. For each indication, the median
numerical score was determined and then assigned to an ap-
propriate use category.
For the conference calls, each technical panelist received
a personalized rating form that indicated his/her rating for
each indication and the distribution of de-identified ratings
of other members of the panel. In addition, the moderator re-
ceived a summary rating form with similar information (in-
cluding panelist identification), along with other statistics
reflecting the level of agreement among technical panelmem-
bers. The level of agreement among panelists, as defined by
RAND, was analyzed for each indication based on the BI-
OMED rule for a panel of 14 to 16 (a simplified RAND
method for determining disagreement).4 Per the BIOMED
definition, agreement was defined as an indication where 4
or fewer panelists’ ratings fell outside the 3-point region
containing the median score. Disagreement was defined as
a situation where at least 5 panelists’ ratings fell in both the
appropriate and the inappropriate categories. Because the
technical panel had 17 representatives, which exceeded the
16 addressed in this rule, an additional level of agreement
analysis as described byRANDwas performed that examined784 The Journal of Thoracic and Cardiovascular Surgthe interpercentile range comparedwith interpercentile range
adjusted for symmetry.4 This information was used by the
moderator to guide the technical panel’s discussion by high-
lighting areas of differences among the panelists.
In developing these appropriate use criteria for coronary
revascularization, the technical panel was asked to assess
whether coronary revascularization for each indication
was appropriate, uncertain, or inappropriate using the
following definition of appropriate use:
Coronary revascularization is appropriate when the ex-
pected benefits, in terms of survival or health outcomes
(symptoms, functional status, and/or quality of life) ex-
ceed the expected negative consequences of the procedure.
The technical panel scored each indication on a scale
from 1 to 9 as follows:
Median Score 7 to 9
Appropriate procedure for specific indication (procedure
is generally acceptable and is a reasonable approach
for the indication).
Median Score 4 to 6
Uncertain for specific indication (proceduremay be gen-
erally acceptable and may be a reasonable approach
for the indication). Uncertainty implies that more re-
search and/or patient information is needed to classify
the indication definitively.
Median Score 1 to 3
Inappropriate procedure for that indication (procedure is
not generally acceptable and is not a reasonable ap-
proach for the indication).
The division of these scores into 3 levels of appropriateness is
somewhat arbitrary, and the numeric designations should be
viewed as a continuum. Further, there is diversity in clinical
opinion for particular clinical scenarios, such that scores in
the intermediate level ofappropriateness shouldbe labeledun-
certain, because critical patient or research data may be lack-
ing or discordant. This designation serves as a prompt to the
field to carry out definitive research investigations whenever
possible. It is anticipated that the AUC reports will continue
to be revised as further data are generated and information
from the implementation of the criteria is accumulated.
To prevent bias in the scoring process, care was taken in
providing objective, nonbiased information, including
guidelines and key references, to the technical panel.
GENERAL ASSUMPTIONS
Specific assumptions are provided that were considered
by the technical panel in rating the relevant clinical scenar-
ios for the appropriate use of revascularization:
1. Each clinical scenario includes the patient’s clinical sta-
tus/symptom complex, ischemic burden by noninvasive
functional testing when presented, burden of coronaryery c April 2012
TABLE A1. CAD prognostic index
Extent of CAD
Prognostic
weight (0–100)
5-Year survival
rate (%)*
1-vessel disease, 75% 23 93
>1-vessel disease, 50% to 74% 23 93
1-vessel disease, 95% 32 91
2-vessel disease 37 88
2-vessel disease, both 95% 42 86
1-vessel disease, 95% proximal LAD 48 83
2-vessel disease, 95% LAD 48 83
2-vessel disease, 95% proximal LAD 56 79
3-vessel disease 56 79
3-vessel disease, 95% in at least 1 63 73
3-vessel disease, 75% proximal LAD 67 67
3-vessel disease, 95% proximal LAD 74 59
CAD, Coronary artery disease; LAD, left anterior descending coronary artery.
*Assuming medical treatment only. Reprinted with permission from Califf et al.5
Patel et al Clinical Guidelinesatherosclerosis as determined by angiography, and inten-
sity of medical therapy in the determination of the appro-
priate use of coronary revascularization.
2. Assume coronary angiography has been performed
when these findings are presented in the indications.
The technical panel should rate the appropriateness of
revascularization based upon the clinical features and
coronary findings, and not the appropriateness of diag-
nostic coronary angiography.
3. Assume left main coronary artery stenosis (greater than
or equal to 50% luminal diameter narrowing) or proxi-
mal LAD stenosis (greater than or equal to 70% luminal
diameter narrowing) is not present unless specifically
noted. Assume no other significant coronary artery steno-
ses are present except those noted in the clinical scenario.
4. The clinical scenarios should be rated based on the pub-
lished literature regarding the risks and benefits of percu-
taneous and surgical coronary revascularization. Note
that specific patient groups not well represented in the lit-
erature are not presented in the current clinical scenarios.
However, the writing group recognizes that decisions
about coronary artery revascularization in such patients
are frequently required. Examples of such patients in-
clude thosewith end-stage renal disease or advanced age.
5. Clinical outcome is related to the extent of coronary ar-
tery disease (Table A1).5 Based on this observation and
clinical guideline recommendations regarding ‘‘border-
line’’ angiographic stenosis (50% to 60%) in epicardial
(non-left main) locations, a significant coronary stenosis
for the purpose of the clinical scenarios is defined as:
+ Greater than or equal to 70% luminal diameter narrow-
ing, byvisual assessment, of an epicardial stenosismea-
sured in the ‘‘worst view’’ angiographic projection.
+ Greater than or equal to 50% luminal diameter nar-
rowing, by visual assessment, of a left main stenosis
measured in the ‘‘worst view’’ angiographic projec-
tion.
6. All patients are receiving standard care, including
guideline-based risk factor modification for primary or
secondary prevention in cardiovascular patients unless
specifically noted.6-10
7. Despite the best efforts of the clinician, all patients may
not achieve target goals for risk factor modification.
However, a plan of care to address risk factors is as-
sumed to be occurring in patients represented in the in-
dications. For patients with chronic stable angina, the
writing group recognizes that there is a wide variance
in the medical therapy for angina. The specific definition
of maximal anti-ischemic medical therapy is presented
in the definition section and includes the use of 2 or
more antianginal medications.
8. Operators performing percutaneous or surgical revascu-
larization have appropriate clinical training and experi-The Journal of Thoracic and Caence and have satisfactory outcomes as assessed by
quality assurance monitoring.11-13
9. Revascularization by either percutaneous or surgical
methods is performed in a manner consistent with estab-
lished standards of care.11-13
10. In the clinical scenarios, no unusual extenuating cir-
cumstances exist (such as inability to comply with
antiplatelet agents, do not resuscitate status, patient un-
willing to consider revascularization, technically not
feasible to perform revascularization, or comorbidities
likely to markedly increase procedural risk substan-
tially) unless specifically noted.DEFINITIONS
A complete set of definitions of terms used throughout
the clinical scenarios is listed in Appendix A. These defini-
tions were provided to and discussed with the technical
panel prior to the rating of indications.Maximal Anti-Ischemic Medical Therapy
As previously stated, the indications assume that patients
are receiving risk factor modification according to
guideline-based recommendations. For the purposes of the
clinical scenarios presented,maximal antianginal medical
therapy is defined as the use of at least 2 classes of ther-
apies to reduce anginal symptoms.Stress Testing and Risk of Findings on Noninvasive
Testing
Stress testing is commonly used for both diagnosis and
risk stratification of patients with coronary artery disease.
Using criteria defined for traditional exercise stress tests14:
Low-risk stress test findings: associated with a cardiac
mortality of less than 1% per yearrdiovascular Surgery c Volume 143, Number 4 785
Clinical Guidelines Patel et alIntermediate-risk stress test findings: associated with
a 1% to 3% per year cardiac mortality
High-risk stress test findings: associated with a greater
than 3% per year cardiac mortality
Examples of findings from noninvasive studies and their
associated level of risk for cardiac mortality are presented in
Table A2.13 As noted in the footnote to this table, for certain
low-risk findings, there may be additional findings that alter
the assessment of risk, but these relationships have not been
well studied. Implicit in these risk definitions is a measure
of the amount of myocardium at risk, or ischemic myocar-
dium. For the purpose of the indications for coronary revas-
cularization, stress test findings are presented by these risk
criteria. For patients without stress test findings, please refer
to the note below on invasive methods of determining he-
modynamic significance. Assume that when prior testing
(including an imaging procedure) is referenced in an indica-
tion, the testing was performed correctly and with sufficient
quality so as to produce a meaningful and accurate result
within the limits of the test performance.
For the purposes of the clinical scenarios in this docu-
ment, patients with both typical and atypical angina are
classified by the feature of the CCS grading system pre-
sented below. Patients with noncardiac chest pain should
be considered to be asymptomatic.Grading of Angina Pectoris by the Canadian
Cardiovascular Society Classification System15
Class I: Ordinary physical activity does not cause an-
gina, such as walking, climbing stairs. Angina occurs
with strenuous, rapid, or prolonged exertion at work
or recreation.
Class II: Slight limitation of ordinary activity. Angina
occurs on walking more than 2 blocks on the level
and climbing more than 1 flight of ordinary stairs at
a normal pace and in normal condition.
Class III:Marked limitations of ordinary physical activ-
ity. Angina occurs on walking 1 or 2 blocks on the
level and climbing 1 flight of stairs in normal condi-
tions and at a normal pace.
Class IV: Inability to carryonanyphysical activitywithout
discomfort—anginal symptoms may be present at rest.High-Risk Features for Short-Term Risk of Death or
Nonfatal MI for UA/NSTEMI16
At least 1 of the following:
 History—accelerating tempo of ischemic symptoms in
preceding 48 hours
 Character of pain—prolonged ongoing (greater than 20
minutes) rest pain786 The Journal of Thoracic and Cardiovascular Surg Clinical findings
+ Pulmonary edema, most likely due to ischemia
+ New or worsening mitral regurgitation murmur
+ S3 or new/worsening rales
+ Hypotension, bradycardia, tachycardia
+ Age greater than 75 years
 Electrocardiogram
+ Angina at rest with transient ST-segment changes
greater than 0.5 mm
+ Bundle-branch block, new or presumed new
+ Sustained ventricular tachycardia
 Cardiac marker
+ Elevated cardiac TnT, TnI, or CK-MB (eg, TnTor TnI
greater than 0.1 ng per mL)TIMI Risk Score—for Patients With Suspected
ACS17
Variables (1 point each)
 Age 65 years
 3 risk factors (hypertension, diabetes mellitus, family
history, lipids, smoking)
 Known CAD (stenosis 50%)
 Aspirin use in past 7 days
 Severe angina (2 episodes within 24 hours)
 ST-segment deviation 0.5 mm
 Elevated cardiac markers
Risk of death or ischemic event through 14 days
 Low: 0–2 (<8.3% event rate)
 Intermediate: 3–4 (<19.3% event rate)
 High: 5–7 (41% event rate)RESULTS OF UPDATED RATINGS
The writing group evaluated the previous 180 clinical
scenarios and identified those where reevaluation, expan-
sion, or consolidation was felt necessary (Table A). Nine
of the 15 updated indications met the definition of agree-
ment as described above. There were no ratings where the
technical panel held such opposing viewpoints that the tech-
nical panel’s votes were determined to be in ‘‘disagree-
ment’’ as defined by the strict RAND definitions and
described previously in the Methods section.
As the majority of the original clinical scenarios and
ratings were not rerated in this update, Table A represents
the focused update indications. In addition, the entire list
of 171 clinical scenarios and their appropriateness scores
are shown below in Tables 1, 2, 3, and 4. Figures 1, 2, 3,
4, and 5 demonstrate gradients in appropriate use rating
by increasingly severe symptom status and ischemic risk,
and by the method of revascularization. These are alsoery c April 2012
TABLE A. Focused update: new or revised indications
Indication Appropriate Use Score (1–9)
Patients With Acute Coronary Syndromes
9.  UA/NSTEMI and low-risk features (eg, TIMI score 2) for short-term risk of death or nonfatal MI
 Revascularization of the presumed culprit artery
U (6)
10.  UA/NSTEMI and intermediate-risk features (eg, TIMI score 3–4) for short-term risk of death or nonfatal
MI
 Revascularization of the presumed culprit artery
A (8)
Patients Without Prior Bypass Surgery Asymptomatic
20.  One- or 2-vessel CAD without involvement of proximal LAD
 No noninvasive testing performed
I (3)
Method of Revascularization: Multivessel CAD, CCS Angina Greater Than or Equal to Class III, and/or Evidence of
Intermediate- to High-Risk Findings on Noninvasive Testing
PCI CABG
62.  Two-vessel CAD with proximal LAD stenosis A (7) A (8)
63.  Three-vessel CAD with low CAD burden (eg, 3 focal stenoses, low SYNTAX score) A (7) A (9)
64.  Three-vessel CAD with intermediate to high CAD burden (eg, multiple diffuse lesions, presence of
CTO, or high SYNTAX score)
U (4) A (9)
65.  Isolated left main stenosis U (6) A (9)
66.  Left main stenosis and additional CADwith low CAD burden (eg, 1- to 2-vessel additional involvement,
low SYNTAX score)
U (5) A (9)
67.  Left main stenosis and additional CAD with intermediate to high CAD burden (eg, 3-vessel
involvement, presence of CTO, or high SYNTAX score)
I (3) A (9)
A, Appropriate; CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; CTO, chronic total occlusion; I, inappropriate; LAD, left anterior descending coronary
artery;MI, myocardial infarction; SYNTAX, Synergy Between PCI With TAXUS and Cardiac Surgery; TIMI, Thrombolysis In Myocardial Infarction;U, uncertain; UA/NSTEMI,
unstable angina/non–ST-segment elevation myocardial infarction.
Patel et al Clinical Guidelinespresented in a format similar to the original document. In
addition to the changes reflected in Table A, the fractional
flow reserve (FFR) cut point was updated from 0.75 toThe Journal of Thoracic and Ca0.80 in indication 22 to reflect new literature since the pub-
lication of the original document and to maintain consis-
tency with guidelines.18rdiovascular Surgery c Volume 143, Number 4 787
Clinical Guidelines Patel et alCORONARY REVASCULARIZATION APPROPRIATE USE CRITERIA (BY INDICATION)TABLE 1. Patients with acute coronary syndromes
New and updated indications are shaded blue. A, Appropriate; CAD, coronary artery disease; HF, heart failure; I, inappropriate; LVEF, left ventricular ejection fraction;MI, myo-
cardial infarction; NSTEMI, non–ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction;
TIMI, Thrombolysis In Myocardial Infarction; U, uncertain; UA, unstable angina.788 The Journal of Thoracic and Cardiovascular Surgery c April 2012
TABLE 2. Patients without prior bypass surgery
(Continued)
Patel et al Clinical Guidelines
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TABLE 2. Continued
New and updated indications are shaded blue. A, Appropriate; CAD, coronary artery disease;CCS, Canadian Cardiovascular Society; I, inappropriate; LAD, left anterior descend-
ing coronary artery; LV, left ventricular; LVEF, left ventricular ejection fraction; U, uncertain. *FFR cut point updated from 0.75 to 0.80 to reflect new literature since publication
of the original document and to maintain consistency with guidelines.18
Clinical Guidelines Patel et al
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TABLE 3. Patients with prior bypass surgery (without acute coronary syndrome)
A, Appropriate; CCS, Canadian Cardiovascular Society; I, inappropriate; LV, left ventricular; U, uncertain.
Patel et al Clinical Guidelines
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TABLE 4. Method of revascularization: Multivessel CAD, CCS angina greater than or equal to class III, and/or evidence of intermediate- to high-
risk findings on noninvasive testing*
New and updated indications are shaded blue. A, Appropriate; CABG, coronary artery bypass graft; CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; CTO,
chronic total occlusion; I, inappropriate; LAD, left anterior descending coronary artery; LIMA, left internal mammary artery; LVEF, left ventricular ejection fraction; PCI, percu-
taneous coronary intervention; SYNTAX, Synergy Between PCI With TAXUS and Cardiac Surgery; U, uncertain. *The 2009 appropriate use criteria.1 separated out diabetes and
normal or depressed LVEF for the indications in this table, but they were combined for the focused update because these clinical variables did not affect the ratings.
FIGURE 1. Appropriate use ratings for revascularization in acute coronary syndromes.* The fact that the use of coronary revascularization for a particular
condition is listed in this figure (appropriate, uncertain, inappropriate) does not preclude the use of other therapeutic modalities that may be equally effective.
See the most current ACCF/AHA UA/NSTEMI and STEMI guidelines.16,23 A, Appropriate; CAD, coronary artery disease; HF, heart failure; I,
inappropriate; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; U, uncertain;
UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction.
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FIGURE 2. Appropriate use ratings by low-risk findings on noninvasive imaging study and asymptomatic (patients without prior bypass surgery).
A, Appropriate; CTO, chronic total occlusion; I, inappropriate; Int., intermediate; Max, maximum; min, minimal; Med., medical; prox. LAD, proximal
left anterior descending artery; Rx, treatment; U, uncertain; vz., vessel.
FIGURE 3. Appropriate use ratings by intermediate-risk findings on noninvasive imaging study and CCS class I or II angina (patients without prior bypass
surgery). A, Appropriate; CCS, Canadian Cardiovascular Society; CTO, chronic total occlusion; I, inappropriate; Int., intermediate; Max, maximum; min,
minimal; Med., medical; prox. LAD, proximal left anterior descending artery; Rx, treatment; U, uncertain; vz., vessel.
Patel et al Clinical Guidelines
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FIGURE 4. Appropriate use ratings by high-risk findings on noninvasive imaging study and CCS class III or IV angina (patients without prior bypass
surgery). A, Appropriate; CCS, Canadian Cardiovascular Society; CTO, chronic total occlusion; I, inappropriate; Int., intermediate; Max, maximum;
min, minimal; Med., medical; prox. LAD, proximal left anterior descending artery; Rx, treatment; U, uncertain; vz., vessel.
FIGURE 5. Method of revascularization of multivessel coronary artery disease. A, Appropriate; CABG, coronary artery bypass grafting; CAD, coronary
artery disease; CTO, chronic total occlusion; I, inappropriate; LAD, left anterior descending artery; PCI, percutaneous coronary intervention; SYNTAX,
Synergy Between PCI With TAXUS and Cardiac Surgery; U, uncertain.
Clinical Guidelines Patel et al
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Patel et al Clinical GuidelinesRATING REVASCULARIZATION METHODS
Mode of Revascularization (Indications 62 to 69)
Recognizing that variability in revascularization methods
is often based upon patient factors and local practice pat-
terns, the majority of indications are not intended to distin-
guish between the specific modes of revascularization
(eg, PCI vs CABG). However, the writing group recognized
that among patients with extensive or complex atheroscle-
rosis, the mode of revascularization is also of interest
when revascularization is deemed appropriate. Therefore,
Table 4 presents clinical scenarios where the technical pan-
elists were asked to consider the appropriate use of PCI and
CABG as the revascularization method independently of
each other (such that each modality would receive separate
scores based on each specific clinical indication). These rat-
ings are not intended to be a competitive ranking of PCI ver-
sus CABG, or to prioritize a specific approach when both
are rated to have the same level of appropriateness.
Many of the known clinical factors that increase the risk
of revascularization are shared between CABG and percuta-
neous methods. In the original AUC for revascularization,
clinical scenarios were developed that included diabetes
and LV function to stratify patients, but when rated, these
features did not result in different ratings and thus were
not used in this focused update. However, in an attempt to
further stratify patients, the SYNTAX score is used in
some of the new clinical scenarios.
The clinical scenarios below specifically apply to patients
with multivessel CAD. It is assumed for these clinical sce-
narios that all patients have unacceptable levels of symp-
toms despite appropriate medical therapy and evidence of
intermediate- to high-risk findings on noninvasive testing.
In other words, the technical panel assumed that revascular-
ization is appropriate and focused on rating the merit of the
different modes with the intent of complete coronary revas-
cularization for each indication.
In addition, it is assumed that no unusual extenuating cir-
cumstances exist (inability to complywith antiplatelet agents,
patient is do not resuscitate status, patient preference strongly
favoring 1 therapy or comorbidities likely to markedly in-
crease procedural risk substantially). As such, the technical
panel rated the appropriateness of PCI and CABG based on
the information in the indication alone, assuming other vari-
ables are not present that would impact the decision.DISCUSSION
The ultimate objective of AUC is to improve patient care
and health outcomes. The ACCF and its collaborators
believe that careful blending of a broad range of clinical ex-
periences and available evidence-based information will
help guide a more efficient and equitable allocation of
healthcare resources in cardiovascular revascularization.
This approach is not intended to diminish the acknowledgedThe Journal of Thoracic and Cadifficulty or uncertainty of clinical decision making. Appro-
priate use criteria are not substitutes for sound clinical judg-
ment and practice experience. It is acknowledged that some
patients seen in clinical practice may not be represented in
the AUC or have extenuating features when compared with
the clinical scenarios presented.
Since the publication of the original coronary revascular-
izationAUC, there has been substantial national focus on the
variability and appropriateness of coronary revasculariza-
tion. The 2009 AUC specifically for coronary revasculariza-
tion by PCI has beenmapped to the National Cardiovascular
Data, Registry (NCDR) CathPCI registry data, and each in-
stitution’s benchmarked results are nowprovided tomember
facilities in quarterly reports as a test qualitymetric. This ini-
tial assessment of PCI appropriateness within the NCDR
datawas also published byChan and colleagues.19 Hospitals
and operators are encouraged to review their specific reports
as part of a quality improvement program to ensure data ac-
curacy and increase the use of appropriate revascularization.
Additionally, the SYNTAX trial, which was not formally
published until 2009,was anticipated to possibly have an im-
pact on the AUC. Despite calls for earlier updates of specific
clinical scenarios, such as the isolated left main coronary ar-
tery revascularization, the writing group awaited the peer-
reviewed publication of both the original trial data and the
intermediate-term follow-up.
This focused update highlights 2 specific areas that were
felt to require reconsideration: (1) specific indications that
represent gaps identified when mapping the 2009 AUC to
the CathPCI registry; and (2) re-evaluation of the indica-
tions for the treatment of multivessel CAD with symptoms
by method (PCI and CABG) of revascularization as a result
of data from the SYNTAX trial.
New Clinical Scenarios to Address Gaps
The 2009 AUC document only had 1 clinical scenario for
UA/NSTEMI and high-risk features, which was graded as
appropriate. The ratings for these new clinical scenarios
(Indications 9 and 10) focus on patients with UA/NSTEMI
and low- or intermediate-risk features as determined by the
TIMI score. Revascularization in such patients with a low-
risk score was graded as uncertain, meaning that revascular-
ization may be reasonable, with the caveat that there is
limited data on clinical benefit. For patients with an
intermediate-risk score, revascularization was rated appro-
priate as it was for patients at high risk (Figure 1).
In the 2009 AUC document, the clinical scenario of an
asymptomatic patient without prior bypass surgery and
with 1- or 2-vessel disease not involving the proximal
LAD in whom no noninvasive testing had been performed
was not evaluated because this clinical scenario was felt
to be uncommon. However, for future mapping of the
AUC to the CathPCI registry, the appropriateness of this
clinical scenario was graded in this focused update andrdiovascular Surgery c Volume 143, Number 4 795
Clinical Guidelines Patel et aldetermined to be inappropriate. This did not affect the ap-
pearance of Figures 2, 3, and 4 below because they
include indications that were not updated.
PCI and CABG in Patients With Multivessel CAD
In this group of ratings, it is assumed that revascularization
is appropriate, and the technical panel rated the
appropriateness of the mode of revascularization indepen-
dently for CABG and PCI (Figure 5). The writing group
and technical panel felt some quantification of CAD burden,
either by description or SYNTAX score, could be helpful to
clinicians. CABG was rated as appropriate in all of the new
clinical scenarios developed,whereas PCIwas rated as appro-
priate only in patientswith 2-vesselCADwith involvement of
the proximal LAD and in patients with 3-vessel disease with
a lowCAD burden. PCI for 3-vessel diseasewith a high CAD
burden, however, was rated as uncertain. PCI for isolated left
main stenosis is nowgradedasuncertain, as are scenarioswith
3-vessel CADwith intermediate to high CAD burden and left
main stenosis and additionalCADwith lowCADburden. PCI
is considered inappropriate for left main stenosis and addi-
tional CAD with intermediate to high CAD burden.
Clinical Judgment and Understanding the AUC
Ratings
Although the appropriate use ratings reflect a general as-
sessment of when revascularization may or may not be use-
ful for specific patient populations, physicians and other
stakeholders should continue to acknowledge the pivotal
role of clinical judgment in determining whether revascu-
larization is indicated for an individual patient. For
example, the rating of a revascularization indication as in-
appropriate or uncertain should not preclude a provider
from performing revascularization procedures when there
are patient- and condition-specific data to support that deci-
sion. Indeed, this may reflect optimal clinical care, if sup-
ported by mitigating patient characteristics. Likewise,
uncertain indications require individual physician judgment
and understanding of the patient to better determine the
usefulness of revascularization for a particular clinical
scenario. The ranking of uncertain (4 to 6) should not be
viewed as excluding the use of revascularization for
such patients. Finally, there may be clinical scenarios in
which the use of coronary revascularization for an indica-
tion considered to be appropriate does not always represent
reasonable practice, such that the benefit of the procedure
does not outweigh the risks. Accordingly, the AUC are in-
tended to evaluate overall patterns of care regarding revas-
cularization rather than adjudicating specific cases. In
situations where there is substantial variation between the
appropriate use rating and what the clinician believes is
the best recommendation for the patient, further consider-
ations or actions such as a second opinion may be appropri-
ate. It is not anticipated that all physicians or facilities will796 The Journal of Thoracic and Cardiovascular Surghave 100% of their revascularization procedures deemed
appropriate. However, related to the overall patterns of
care, if the national average of appropriate procedure rat-
ings is 80%, eg, and a physician or facility has only
a 40% rate of appropriate procedures, further examination
of the patterns of care may be warranted and helpful.
Stable Ischemic Heart Disease With Prior CABG
The writing group did not feel the focused update needed
to address any clinical scenarios in patients with stable is-
chemic heart disease and prior CABG. These indications
from the prior document show a pattern similar to that
seen in patients without prior CABG; the presence of
high-risk findings on noninvasive testing, higher severity
of symptoms, or an increasing burden of disease in either
the bypass grafts or native coronaries increased the likeli-
hood of an appropriate rating. The only inappropriate rat-
ings in patients with prior CABG were noted in patients
receiving no or minimal anti-ischemic therapy or having
low-risk findings on noninvasive testing. More uncertain
ratings occurred in this group of patients, reflecting their
higher complexity, higher risk, and the limited availability
of published evidence regarding management outcome.
Application of Criteria
There are many potential applications for the AUC.
Clinicians can use the ratings for decision support or as
an educational tool when considering the need for revascu-
larization. Moreover, these criteria can be used to facilitate
discussion with patients and/or referring physicians about
the need for revascularization. Facilities and payers may
choose to use these criteria either prospectively in the de-
sign of protocols or pre-authorization procedures, or retro-
spectively for quality reports. It is hoped that payers
would use these criteria to ensure that their members re-
ceive necessary, beneficial, and cost-effective cardiovascu-
lar care, rather than for other purposes.
It is expected that services performed for appropriate in-
dications will receive reimbursement. In contrast, services
performed for inappropriate indications may require addi-
tional documentation to justify payment because of the
unique circumstances or the clinical profile that may exist
in such a patient. This additional documentation should
not be required for uncertain indications. It is critical to em-
phasize that the writing group, technical panel, AUC Task
Force, and clinical community do not believe an uncertain
rating justifies denial of reimbursement for revasculariza-
tion. Rather, uncertain ratings are those in which the avail-
able data vary and many other factors exist that may affect
the decision to perform or not perform revascularization.
The opinions of the technical panel often varied for these in-
dications, reflecting that additional research is needed. Indi-
cations with high clinical volume that are rated as uncertain
identify important areas for further research. The AUCery c April 2012
Patel et al Clinical Guidelineswriting group and technical panel favor the collaborative in-
teraction of cardiac surgeons and interventional cardiolo-
gists Heart Team approach regarding revascularization
decisions in complex patients or coronary anatomy.
When evaluating physician or facility performance, AUC
should be used in conjunction with efforts that lead to quality
improvement. Prospective pre-authorization procedures, if
put in place, are most effective once a retrospective review
has identifieda patternofpotential inappropriate use.Because
these criteria are based on current scientific evidence and the
deliberations of the technical panel, they should be used pro-
spectively to generate future discussions about reimburse-
ment, but should not be applied retrospectively to cases
completed before issuance of this report or documentation
of centers/providers performing an unexpectedly high pro-
portion of inappropriate cases as compared with their peers.
The writing group recognizes that these criteria will be
evaluated during routine clinical care. To that end, specific
data fields such as symptom status, presence or absence of
acute coronary syndrome, history of bypass surgery, extent
of ischemia on noninvasive imaging, CAD burden, and de-
gree of antianginal therapy are anticipated to provide suffi-
cient detail to determine individual appropriate use ratings.
Because a reasonable and tolerated dose of antianginal ther-
apy may vary significantly among different patients, the
writing group continues to recommend the use of 2 classes
of antianginal therapies as a minimum standard for medical
therapy. The writing group also recognizes all data (eg,
visual assessment of stenosis severity, interpretation of
noninvasive imaging, symptom severity) collected to assess
appropriate use relies on its content accurately reflecting ac-
tual patient characteristics. Any current variability in these
data points need to be addressed before accurate determina-
tion of appropriate use can be provided.
The primary objective of this report is to provide guidance
regarding the suitability of coronary revascularization for di-
verse clinical scenarios. As with previous AUC documents,
consensus among the technical panelmemberswas desirable,
but an attempt to achieve complete agreement within this di-
verse panel would have been artificial and was not the goal of
the process. Two rounds of ratings with substantial discussion
among the technical panel members between the ratings did
lead to some consensus among panelists. However, further at-
tempts to drive consensus would have diluted true differences
in opinion among panelists and, therefore, was not under-
taken. Moreover, remarkable concordance between the ap-
propriateness ratings from the original criteria and 85
cardiologists not participating in the process, and blinded to
the initial results, has been documented.20
Future research analyzing patient outcomes for indica-
tions rated as appropriate will help ensure the equitable
and efficient allocation of resources for coronary revascu-
larization. Review of appropriateness patterns may also im-
prove understanding of regional variations in the use ofThe Journal of Thoracic and Carevascularization as highlighted in the Dartmouth Atlas
Project.21 Further exploration of the indications rated as
uncertain will help generate the information required to fur-
ther define the appropriate use of coronary revasculariza-
tion. Additionally, the criteria will need to be updated
with the publication of ongoing trials in coronary revascu-
larization and new clinical practice guidelines. For addi-
tional information and discussion of the literature, please
see the ACCF/AHA PCI and CABG guidelines.12,13
In conclusion, this document represents the current un-
derstanding of the clinical benefit of coronary revasculari-
zation with respect to health outcomes and survival. It is
intended to provide a practical guide to clinicians and
patients when considering revascularization. As with other
AUC, the results of some of these ratings will require re-
search and further evaluation to provide the greatest infor-
mation and benefit to clinical decision making.APPENDIX A: ADDITIONAL CORONARY
REVASCULARIZATION DEFINITIONS
Angina/Chest Pain Classification
Angina is a syndrome typically noted to include discom-
fort in the chest, jaw, shoulder, back, or arm that is aggravated
by exertion or emotional stress and relieved by nitroglycerin.
The quality of the discomfort, provoking factors, and reliev-
ing factors are used to define typical, atypical, and noncar-
diac chest pain. Atypical angina is generally defined by 2
of the above 3 characteristics, and noncardiac chest pain is
generally defined as chest pain that meets 1 or none of the
above criteria. These definitions are presented below.
Clinical Classification of Chest Pain22:
 Typical Angina (Definite): Defined as (1) substernal
chest pain or discomfort that is (2) provoked by exer-
tion or emotional stress and (3) relieved by rest and/or
nitroglycerin.
 Atypical Angina (Probable): Chest pain or discom-
fort that lacks 1 of the characteristics of definite or
typical angina.
 NonanginalChest Pain:Chest pain or discomfort that
meets 1 or none of the typical angina characteristics.
The writing group assumes that noninvasive assessments of
coronary anatomy (ie, cardiac computed tomography, car-
diac magnetic resonance angiography) provide anatomic in-
formation that is potentially similar to x-ray angiography.
However, these modalities do not currently provide infor-
mation on ischemic burden and are not assumed to be pres-
ent in the clinical scenarios.
Invasive Methods of Determining Hemodynamic
Significance
Thewriting group recognizes that not all patients referred
for revascularization will have previous noninvasive testing.rdiovascular Surgery c Volume 143, Number 4 797
TABLE A2. Noninvasive risk stratification
High-risk (>3% annual mortality rate)
1. Severe resting left ventricular dysfunction (LVEF<35%)
2. High-risk treadmill score (score 11)
3. Severe exercise left ventricular dysfunction (exercise LVEF<35%)
4. Stress-induced large perfusion defect (particularly if anterior)
5. Stress-induced multiple perfusion defects of moderate size
6. Large, fixed perfusion defect with LV dilation or increased lung uptake
(thallium-201)
7. Stress-induced moderate perfusion defect with LV dilation or increased
lung uptake (thallium-201)
8. Echocardiographic wall motion abnormality (involving>2 segments)
developing at low dose of dobutamine (10mg/kg/min) or at a low heart
rate (<120 beats/min)
9. Stress echocardiographic evidence of extensive ischemia
Intermediate-risk (1% to 3% annual mortality rate)
1. Mild/moderate resting left ventricular dysfunction (LVEF 35% to 49%)
2. Intermediate-risk treadmill score (score between11 and<5)
3. Stress-induced moderate perfusion defect without LV dilation or
increased lung intake (thallium-201)
4. Limited stress echocardiographic ischemia with a wall motion
abnormality only at higher doses of dobutamine involving less than or
equal to 2 segments
Low-risk (<1% annual mortality rate)
1. Low-risk treadmill score (score 5)
2. Normal or small myocardial perfusion defect at rest or with stress*
3. Normal stress echocardiographic wall motion or no change of limited
resting wall motion abnormalities during stress*
LV, Left ventricular; LVEF, left ventricular ejection fraction. *Although the published
data are limited, patients with these findings will probably not be at low risk in the
presence of either a high-risk treadmill score or severe resting left ventricular dys-
function (LVEF<35%). Reprinted with permission from Patel et al.1
* Participated in the 2009 Appropriate Use Criteria for Coronary Revascularization
only.
Clinical Guidelines Patel et alIn fact, there are several situations in which patients may be
appropriately referred for coronary angiography based on
symptom presentation and a high pretest probability of cor-
onary artery disease. In these settings, there may be situa-
tions where angiography shows a coronary narrowing of
questionable hemodynamic importance in a patient with
symptoms that can be related to myocardial ischemia. In
such patients, the use of additional invasive measurements
(such as fractional flow reserve or intravascular ultrasound)
at the time of diagnostic angiographymay be very helpful in
further defining the need for revascularization and
substituted for stress test findings (Table A2).
APPENDIX B: ADDITIONAL METHODS
See the earlierMethods section of the report for a descrip-
tion of technical panel selection, indication development,
scope of indications, and rating process.
Relationships With Industry and Other Entities
The American College of Cardiology Foundation and its
partnering organizations rigorously avoid any actual, per-
ceived, or potential conflicts of interest thatmight arise as a re-
sult of anoutside relationship or personal interest of amember
of the technical panel. Specifically, all panelists are asked to798 The Journal of Thoracic and Cardiovascular Surgprovide disclosure statements of all relationships that might
be perceived as real or potential conflicts of interest. These
statements were reviewed by the AUC Task Force, discussed
with all members of the technical panel at the face-to-face
meeting, and updated and reviewed as necessary. A table of
disclosures by all participants, who are listed in Appendix
C, in the Appropriate Use Criteria for Coronary Revasculari-
zation can be found in Appendix D. In addition, to ensure
complete transparency, complete disclosure information—
including relationships not pertinent to this document—is
available online as a document supplement.
Literature Review
The technical panel members were asked to refer to the
relevant guidelines for a summary of the relevant literature,
guideline recommendation tables, and reference lists pro-
vided for each indication table when completing their rat-
ings (Online Appendix).
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School of Medicine; and Director, Cardiology Division,
Scott & White Clinic, Temple, TX
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